Tango Therapeutics (TNGX) 44th Annual J.P. Morgan Healthcare Conference summary

Leadership and Strategic Direction

• CEO role transitioned from Barbara Weber to Malte Peters, who brings extensive clinical development and regulatory experience from MorphoSys, Sandoz, and Novartis Oncology, ensuring continuity and expertise in late-stage development.

• Leadership change aligns with the shift from early development to late-phase drug development and regulatory focus, aiming to drive the next phase of growth with innovative combination regimens.

• Malte Peters has been involved with the company since 2018 and is familiar with the board and development team, ensuring a smooth transition.

Pipeline Highlights and Clinical Progress

• Pipeline targets MTAP-deleted cancers, with vopimetostat (TNG462) in dose expansion and TNG908 in dose escalation for brain-penetrant activity.

• Vopimetostat shows a 27% response rate and 6.4-month median progression-free survival in monotherapy, and a 49% response rate with 9.1-month mPFS in a histology-selective cohort.

• In 2L pancreatic cancer, vopimetostat achieved a 25% ORR and 7.2-month mPFS, more than doubling historical standard-of-care outcomes.

• Combination studies with Revolution Medicines' RAS inhibitors in pancreatic and lung cancer show promising tolerability and early clinical activity, supporting chemo-sparing regimens.

• TNG456, a brain-penetrant PRMT5 inhibitor, is in phase 1/2 for glioblastoma with FDA Fast Track and Orphan Drug designations; TNG961, an HBS1L degrader, is IND-ready with strong preclinical activity.

Market Opportunity and Scientific Rationale

• MTAP deletion is a common genetic alteration in several cancers, affecting 60,000 patients annually in the US, with high prevalence in pancreatic, lung, and glioblastoma.

• MTAP deletion confers sensitivity to PRMT5 inhibitors, creating a large development opportunity; preclinical data do not support use in non-MTAP-deleted tumors.